FDA Seeks Regulatory Flexibility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Seeks Regulatory Flexibility
Quality-by-design submissions may reduce supplements and improve change management.


Pharmaceutical Technology
Volume 3, Issue 32

So far, it has been up to each company to decide whether it will adopt QbD approaches and develop continuous quality-control operations. Proposals that mandate such activities will surely generate opposition on many fronts. FDA's challenge is to devise a strategy that offers regulatory relief to companies that adopt modern manufacturing practices without penalizing those that do not.

In addition, a regulatory change that even remotely appears to compromise drug safety will raise a red flag. In the current political climate, critics of industry and FDA could regard modified reporting rules for manufacturers as allowing production-system changes without appropriate oversight of safety effects.

A recent FDA proposal to clarify when manufacturers can file CBEs for labeling changes that reflect new safety information was blasted on Capitol Hill. Congressional leaders objected that the proposed rule would encourage pharmaceutical companies to hide drug-safety information and protect marketers of unsafe products from legal action. Though the point of reducing supplements is to help FDA handle its expanding workload and to encourage modern manufacturing practices, even the best intentions face intense scrutiny these days.

Streamlining adverse events

Skepticism about FDA regulatory actions may affect efforts to streamline the agency's complex and costly process for adverse event (AE) reporting. Current rules require manufacturers to submit reports that involve serious and unexpected events within 15 days. Less serious problems may be filed in quarterly reports. After a product has been marketed for three years, minor problems may be filed annually.

In the US, most AE data are fed into FDA's Adverse Event Reporting System (AERS). AERS holds about 4 million case reports, and this number is growing by about 300,000 reports each year. This spontaneous reporting system relies on patients and healthcare professionals to detect and inform manufacturers and regulatory authorities of problems related to medical products.

AERS is considered effective at detecting signals of rare, unexpected drug-safety problems such as new drug interactions and confusion about product names and labeling. But reports are often incomplete. In addition, the system does not address safety issues that involve heavy background noise (e.g., cardiac problems related to COX-2 inhibitors or diabetes drugs).

In reauthorizing the Prescription Drug User Fee program under the FDA Amendments Act of 2007, Congress approved additional funds to expand and improve the AERS system. The legislation also supports developing an active AE detection system linked to health-system and government healthcare databases.

As part of this effort to modernize drug-safety oversight, legislators instructed FDA to engage outside experts to assess the value of AERS. Experts will determine how long the current system takes to identify safety problems and the extent that passive or spontaneous reports from patients and health professionals lead to regulatory action.

FDA held a public workshop in January to gain input on how to assess the current AE reporting system, as well as its capabilities and shortcomings. Solomon Iyasu, of CDER's Office of Safety and Epidemiology (OSE), explained that AERS is valuable because it covers all FDA-regulated products. Moreover, the system reaches a large real-world patient population, including those who take drugs for off-label uses.

At the same time, many safety problems go undetected, and reports filed with AERS are often uninformative.

Despite these and other weaknesses, the healthcare community believes that spontaneous AE reporting should be retained and strengthened. Practitioners and patients say a new, active safety detection system should complement what already exists. OSE researchers found that safety issues occur throughout a drug's life cycle and that many serious issues emerge after drugs are on the market for more than 13 years.

How can regulators make AERS more effective and efficient? At the AE workshop, Ralph Edwards of the World Health Organization commented that the massive volume of reports in AERS "varies from utter nonsense to real gold." The challenge is to identify those "utterly ridiculous" reports and avoid using them to make regulatory decisions.

Jill Wechsler is Pharmaceutical Technology's Washington editor, 7715 Rocton Ave., Chevy Chase, MD 20815, tel. 301.656.4634,


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
17%
Protecting the supply chain
50%
Expedited reviews of drug submissions
0%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: Pharmaceutical Technology,
Click here